Cancer Harboring Braf Alterations clinical trials

Explore recruiting cancer harboring braf alterations clinical trials.

Recruiting cancer harboring braf alterations studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cancer Harboring Braf Alterations trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participants with cancer harboring BRAF alterations

Spain, Italy, France, Germany, Sweden, Norway +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Cancer Harboring Braf Alterations trials by city

Cancer Harboring Braf Alterations in Toronto Cancer Harboring Braf Alterations in Vancouver Cancer Harboring Braf Alterations in Montreal Cancer Harboring Braf Alterations in Calgary Cancer Harboring Braf Alterations in Edmonton Cancer Harboring Braf Alterations in Ottawa Cancer Harboring Braf Alterations in Winnipeg Cancer Harboring Braf Alterations in Quebec City Cancer Harboring Braf Alterations in Hamilton Cancer Harboring Braf Alterations in Kitchener Cancer Harboring Braf Alterations in London Cancer Harboring Braf Alterations in Halifax Cancer Harboring Braf Alterations in New York Cancer Harboring Braf Alterations in Los Angeles Cancer Harboring Braf Alterations in Chicago Cancer Harboring Braf Alterations in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease